| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | lukF |
| Uniprot No | P31715 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-323aa |
| 氨基酸序列 | AEGKITPVSVKKVDDKVTLYKTTATADSDKFKISQILTFNFIKDKSYDKDTLVLKATGNINSGFVKPNPNDYDFSKLYWGAKYNVSISSQSNDSVNAVDYAPKNQNEEFQVQNTLGYTFGGDISISNGLSGGLNGNTAFSETINYKQESYRTLSRNTNYKNVGWGVEAHKIMNGWGPYGRDSFHPTYGNELFLAGRQSSAYAGQNFIAQHQMPLLSRSNFNPEFLSVLSHRQDRAKKSKITVTYQREMDLYQIRWNGFYWAGANYKNFKTRTFKSTYEIDWENHKVKLLDTKETENNK |
| 预测分子量 | 54.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于lukF重组蛋白的3篇代表性文献(内容基于公开研究整理，非真实文献)：
1. **文献名称**：*Structural and Functional Analysis of the Panton-Valentine Leukocidin Component LukF*
**作者**：Baba T. et al.
**摘要**：通过X射线晶体学解析了重组LukF蛋白的三维结构，揭示了其与细胞膜结合的分子机制，并证明其与LukS协同作用导致白细胞溶解。
2. **文献名称**：*Recombinant Expression of Staphylococcus aureus LukF in Escherichia coli for Antibody Production*
**作者**：DuMont A.L. et al.
**摘要**：研究利用大肠杆菌系统高效表达重组LukF蛋白，纯化后用于制备特异性抗体，为PVL毒素的免疫检测提供了工具。
3. **文献名称**：*Development of an ELISA for Detection of LukF-Specific Antibodies in Human Sera*
**作者**：Kong C. et al.
**摘要**：基于重组LukF蛋白建立ELISA检测方法，用于分析金黄色葡萄球菌感染患者血清中的抗体水平，证实其临床诊断潜力。
4. **文献名称**：*Role of Recombinant LukF in Neutrophil Apoptosis and Inflammatory Response*
**作者**：Diep B.A. et al.
**摘要**：通过体外实验证明，重组LukF蛋白可诱导中性粒细胞凋亡并增强炎症反应，提示其在金黄色葡萄球菌致病机制中的关键作用。
(注：以上文献为示例性质，具体研究请参考真实数据库如PubMed。)
LukF is a key component of the bi-component leukocidin family produced by *Staphylococcus aureus*, a pathogenic bacterium associated with skin infections, pneumonia, and sepsis. Leukocidins, including the Panton-Valentine leukocidin (PVL), LukAB, and LukED, function as pore-forming toxins (PFTs) that target host immune cells. These toxins typically consist of two distinct subunits, designated as "S" (slow-eluting) and "F" (fast-eluting), which assemble on host cell membranes to form lytic pores. LukF pairs with LukS-type subunits (e.g., LukS-PV in PVL) to mediate cell lysis by disrupting membrane integrity, contributing to immune evasion and bacterial virulence.
Recombinant LukF protein is generated through genetic engineering, often expressed in *E. coli* or other heterologous systems. The gene encoding LukF is cloned into expression vectors, followed by protein purification using affinity chromatography. Recombinant technology allows for high-purity, scalable production of LukF, circumventing risks associated with isolating native toxins from pathogenic *S. aureus*. This approach facilitates functional and structural studies, enabling researchers to dissect toxin mechanisms, host receptor interactions (e.g., binding to CCR5 or CD11b), and pore-formation dynamics. Structural analyses, such as X-ray crystallography, reveal LukF's β-barrel fold and conformational changes during pore assembly.
Recombinant LukF is instrumental in developing therapeutic strategies, including monoclonal antibodies, inhibitors, and vaccines targeting staphylococcal infections. It also serves as a critical tool in diagnostic assays to detect *S. aureus* virulence factors. Studies using recombinant LukF have advanced understanding of bacterial pathogenesis, host-pathogen interactions, and immune responses, highlighting its dual role as a virulence factor and a target for antimicrobial innovation.
×
